Health
Moderna and Merck's Cancer Vaccine Shows Promise
Moderna and Merck’s personalized mRNA cancer vaccine demonstrated significant efficacy in a late-stage melanoma trial, extending patient survival compared to Keytruda alone.
Coverage timeline — 2 articles
STAT News
A personalized mRNA cancer vaccine succeeded in a late-stage melanoma study, results that could herald a new, powerful approach in oncology.
2026-08-19 10:45 UTC
CNBC
The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone.
2026-08-19 10:49 UTC